Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. Insulin resistance and obesity-related inflammatory status, associated with genetic, dietary, and lifestyle factors, are involved in its pathogenesis. There is no consensus concerning the pharmacological treatment of NAFLD. However, the international guidelines agree to define a dietetic nutritional management to achieve weight loss, as an essential component of any therapeutic strategy. Areas covered: An overview on the beneficial effects of the Mediterranean diet in the prevention and treatment of NAFLD. Expert commentary: On the basis of its components, the literature reports the beneficial effects of the Mediterranean diet in preventing ma...
Nutritional habits modifications have shown an important impact in preventing and ameliorating metab...
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is ...
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of the population and...
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. I...
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. I...
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. I...
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. The mechanisms...
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. The mechanisms...
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. The mechanisms...
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is ...
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, characterized ...
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, characterized ...
Lifestyle interventions remain the first-line treatment for non-alcoholic fatty liver disease (NAFLD...
Lifestyle interventions remain the first-line treatment for non-alcoholic fatty liver disease (NAFLD...
Lifestyle interventions remain the first-line treatment for non-alcoholic fatty liver disease (NAFLD...
Nutritional habits modifications have shown an important impact in preventing and ameliorating metab...
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is ...
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of the population and...
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. I...
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. I...
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. I...
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. The mechanisms...
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. The mechanisms...
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. The mechanisms...
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is ...
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, characterized ...
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, characterized ...
Lifestyle interventions remain the first-line treatment for non-alcoholic fatty liver disease (NAFLD...
Lifestyle interventions remain the first-line treatment for non-alcoholic fatty liver disease (NAFLD...
Lifestyle interventions remain the first-line treatment for non-alcoholic fatty liver disease (NAFLD...
Nutritional habits modifications have shown an important impact in preventing and ameliorating metab...
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is ...
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of the population and...